article thumbnail

Omnicell and Fresenius Kabi Join Forces to Improve Controlled Substance Management

Omnicell

Tara Plappert Product Marketing Manager Hospitals and clinics face a significant challenge when dealing with controlled substances. In 2019, more than 148 million doses of medicine were lost , endangering both patients and employees. And according to the 2019 Drug Diversion Digest , 47.2

article thumbnail

Another Mystery Solved: DEA Issues a Final Decision Revoking Morris & Dickson’s Registration: Or Has It?

The FDA Law Blog

On May 24, 2019, Morris & Dickson paid a $22 million civil penalty related to the failure to report suspicious orders and ignoring certain red flags in the distribution of controlled substances. It has continued to serve customers who have relied on the distributor to supply controlled substances and other medicine.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Harmony’s sleep disorder drug Wakix gets US label extension

pharmaphorum

Wakix (pitolisant) was first approved in August 2019 for treatment of excessive sleepiness in adults with narcolepsy. It is the only FDA-approved drug to treat cataplexy associated with narcolepsy not scheduled as a controlled substance by the US Drug Enforcement Administration.

article thumbnail

Summer 2021 – Transforming Pharmacy Through Innovation and Superior Customer Experience

Omnicell

Expanded Automation With more than 148 million doses of medicine lost in 2019 , controlled substance management remains a significant challenge in the U.S. The Controlled Substance Dispenser helps to better manage inventory, reduce the chance of diversion, and save nursing time.

article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

Harmony Biosciences introduced Wakix to the market in 2019 as the first non-controlled substance for the treatment of narcolepsy. That’s an objectively long time to have exclusivity of a drug that was first synthesised nearly 100 years ago. Competition starts to heat up.

FDA 116
article thumbnail

Psychedelic research: evaluating the fast-evolving regulatory roadmap

European Pharmaceutical Review

Most psychedelic drugs are Schedule I controlled substances, which means that very strict legal and regulatory controls accompany their use” Some psychedelics originate in nature and have been used by Indigenous cultures for thousands of years; others are manipulated or manufactured.

article thumbnail

HPM Welcomes 15-Year DOJ Veteran, John W.M. Claud, to the Firm

The FDA Law Blog

He also held leading roles in DOJ’s response to multiple significant national health crises, including the COVID-19 pandemic, the 2019 EVALI vaping crisis, and the 2012 New England Compounding Center fungal meningitis outbreak.